PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 127 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $62,000 | +3000.0% | 10,126 | +1825.1% | 0.00% | – |
| Q1 2019 | $2,000 | -93.1% | 526 | -92.4% | 0.00% | -100.0% |
| Q4 2018 | $29,000 | -81.8% | 6,895 | -74.2% | 0.00% | -87.5% |
| Q4 2017 | $159,000 | -55.3% | 26,747 | -29.1% | 0.01% | -68.0% |
| Q1 2017 | $356,000 | +2866.7% | 37,749 | +1848.8% | 0.02% | +2400.0% |
| Q3 2016 | $12,000 | -93.0% | 1,937 | -93.5% | 0.00% | -88.9% |
| Q3 2015 | $171,000 | -82.9% | 29,982 | -77.7% | 0.01% | -81.6% |
| Q2 2015 | $1,002,000 | – | 134,322 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |